HPLC法测定头孢曲松钠和有关物质含量的改进

目的对HPLC法测定头孢曲松钠和有关物质含量的方法进行改进。方法选用Thermo BDS HYPERSIL C18（250mm×4．6mm,5μm）色谱柱,流动相为甲醇．0．2％磷酸（30：70）,检测波长为254nm;流速为1．0mL／min。结果本品中头孢曲松钠含量测定线性范围为4．580—6870ng（r=1．000）,平均回收率为99．7％（RSD=0．5％,n=6）;检测限和定量限分别为0．09ng和0．31ng。结论该改进后的测定方法更快速、准确,重复性好;检测结果同《中国药典》（2010年版）的比较,基本一致。     

盐酸莫西沙星氯化钠注射液无菌检查方法的建立

目的建立盐酸莫西沙星氯化钠注射液无菌检查方法。方法参照《中国药典》2010年版方法进行试验。结果采用薄膜过滤法（冲洗量：400ml／膜）并结合中和法（每100ml培养基加入：0．1mol／L的硫酸锰溶液5ml）即可消除样品对各菌株的抗菌活性。结论建立的方法可行,可用于盐酸莫西沙星氯化钠注射液无菌检查。     

氯胺酮相关性膀胱炎3例报告并文献复习

目的：分析3例氯胺酮相关性膀胱炎的临床表现、诊断、治疗,以提高对该病的确诊率及疗效。方法对2012年8月~2013年10月本科收治的3例氯胺酮相关性膀胱炎患者进行分析并对相关文献进行复习。结果尿频、尿急、尿痛伴或不伴下腹部、盆腔疼痛或血尿为氯胺酮相关性膀胱炎的主要症状,膀胱容量变小、膀胱壁增厚或可伴有上尿路积水为主要改变,戒食氯胺酮及碱化利多卡因结合膀胱水扩张等综合治疗为主要方法。结论对不明原因明显下尿路症状而治疗效果不佳的年轻患者,应考虑氯胺酮相关性膀胱炎的可能,系统追问病史有助于诊断,多手段综合治疗对缓解症状有明显疗效。     

奥曲肽联合泮托拉唑钠治疗急性胰腺炎的效果观察

目的探讨奥曲肽联合泮托拉唑钠治疗急性胰腺炎的临床效果。方法选择本院92例急性胰腺炎患者．随机分为观察组和对照组,各46例,对照组给予乌司他丁、奥曲肽等常规治疗,观察组在对照组治疗基础上加用泮托拉唑钠治疗,观察两组患者治疗效果。结果观察组血淀粉酶、尿淀粉酶、血脂肪酶及血清钙恢复正常时间均短于对照组（P〈0．05）;观察组痊愈率为78．26％,显著高于对照组的52．17％（P〈0．05）;观察组患者发热、腹痛、腹胀、恶心呕吐等症状改善时间短于对照组（P〈0．05）;观察组患者治疗后IL-6、CRP及TNF-α水平均低于对照组（P〈0．05）。结论奥曲肽联合泮托拉唑钠治疗急性胰腺炎可减轻胰腺及周围组织损伤,改善炎症,从而加快机体恢复。提高治疗效果。     

热毒宁注射液联合头孢地嗪钠治疗儿童支气管肺炎的临床效果分析

目的：分析热毒宁注射液联合头孢地嗪钠治疗儿童支气管肺炎的临床效果。方法选取2012年2月~2014年2月本院住院部收治的120例支气管肺炎患儿,按照抽样法随机分为对照A组、对照B组和研究组,每组各40例;3组患儿均给予对症治疗,且对照A组给予热毒宁注射液治疗,对照B组给予头孢地嗪钠治疗,研究组给予热毒宁注射液＋头孢地嗪钠治疗,分析3组患儿复诊检查资料及不良反应的情况。结果研究组患儿治疗后咳嗽控制效果均明显优于其他两组,差异有统计学意义（P〈0.05）;研究组患儿的住院时间及住院费用明显少于其他两组,差异有统计学意义（P〈0.05）。结论热毒宁注射液联合头孢地嗪钠治疗儿童支气管肺炎的临床协同效果显著。     

黄酮类成分黄芩素、槲皮素、丹参素钠对吸烟致细胞毒性和DNA损伤的保护作用

目的评价吸烟致细胞毒性和DNA损伤以及黄酮类成分黄芩素、槲皮素、丹参素钠的保护作用。方法以自动吸烟机按照FTC协议吸烟产生的主流烟雾在线染毒B-16细胞和人颊黏膜细胞两种真核细胞,通过MTT比色法和单细胞凝胶电泳法检测吸烟所致的细胞毒性和DNA损伤,并考察黄芩素、槲皮素、丹参素钠的保护作用。结果吸烟可致体外培养的B-16细胞活力明显下降,两种细胞的DNA明显损伤。随着烟气作用时间的延长,表征细胞内DNA损伤程度的彗星尾矩、Olive尾矩都有增加;1 mmol/L槲皮素、黄芩素和丹参素均可明显缓解吸烟引起的细胞毒性和DNA损伤,对B-16细胞的活力提升50%左右,对人颊黏膜细胞的DNA保护效果超过60%。结论吸烟可致细胞毒性和细胞DNA损伤,但是黄酮类成分黄芩素、槲皮素、丹参素钠均对细胞和DNA具有保护作用。     

N-乙酰半胱氨酸预防亚硒酸钠诱导大鼠白内障的研究

目的 对亚硒酸钠诱导白内障大鼠采用N-乙酰半胱氨酸进行预防性治疗,探讨N-乙酰半胱氨酸对白内障大鼠模型氧化损伤和晶状体浑浊程度的影响。方法 30只SD乳鼠随机分为3组,模型组ip 3.46 mg/kg亚硒酸钠溶液造模后,ip 0.1 mL/10 g生理盐水;实验组ip N-乙酰半胱氨酸10 mg/g,30 min ip亚硒酸钠溶液造模;对照组ip 0.1 mL/10 g生理盐水。所有动物均为隔日注射,连续6次。比较大鼠晶状体浑浊程度和SOD活性、NOS活性和MDA水平。结果 在晶状体核区、后囊区、前囊区+后囊区、前囊区+皮质区+核区+后囊区中,实验组与模型组比较得分差异具有统计学意义（P<0.05）;实验组SOD活性和MDA活性与模型组比较差异均具有统计学意义（P<0.05）。结论 N-乙酰半胱氨酸能够预防后囊和核区白内障的发生,其作用是通过减少MDA水平、提高SOD活性、改善氧化应激实现的。     

Tetracalcium Phosphate/Monetite/Calcium Sulfate Hemihdrate Biocement Powder Mixtures Prepared by the One-Step Synthesis for Preparation of Nanocrystalline Hydroxyapatite Biocement-Properties and In Vitro Evaluation

A modified one-step process was used to prepare tetracalcium phosphate/monetite/calcium sulfate hemihydrate powder cement mixtures (CAS). The procedure allowed the formation of monetite and calcium sulfate hemihydrate (CSH) in the form of nanoparticles. It was hypothesized that the presence of nanoCSH in small amounts enhances the in vitro bioactivity of CAS cement in relation to osteogenic gene markers in mesenchymal stem cells (MSCs). The CAS powder mixtures with 15 and 5 wt.% CSH were prepared by milling powder tetracalcium phosphate in an ethanolic solution of both orthophosphoric and sulfuric acids. The CAS cements had short setting times (around 5 min). The fast setting of the cement samples after the addition of the liquid component (water solution of NaH₂PO₄) was due to the partial formation of calcium sulfate dihydrate and hydroxyapatite before soaking in SBF with a small change in the original phase composition in cement powder samples after milling. Nanocrystalline hydroxyapatite biocement was produced by soaking of cement samples after setting in simulated body fluid (SBF). The fast release of calcium ions from CAS5 cement, as well as a small rise in the pH of SBF during soaking, were demonstrated. After soaking in SBF for 7 days, the final product of the cement transformation was nanocrystalline hydroxyapatite. The compressive strength of the cement samples (up to 30 MPa) after soaking in simulated body fluid (SBF) was comparable to that of bone. Real time polymerase chain reaction (RT-PCR) analysis revealed statistically significant higher gene expressions of alkaline phosphatase (ALP), osteonectin (ON) and osteopontin (OP) in cells cultured for 14 days in CAS5 extract compared to CSH-free cement. The addition of a small amount of nanoCSH (5 wt.%) to the tetracalcium phosphate (TTCP)/monetite cement mixture significantly promoted the over expression of osteogenic markers in MSCs. The prepared CAS powder mixture with its enhanced bioactivity can be used for bone defect treatment and has good potential for bone healing.     

Exercise‐induced ventricular tachycardia in a case with hypertrophic cardiomyopathy taking cibenzoline

We report a 17‐year‐old woman with hypertrophic cardiomyopathy (HCM) successfully resuscitated from ventricular fibrillation while taking cibenzoline. During exercise–stress testing before implanting an implantable cardioverter–defibrillator, ventricular tachycardia was induced and thought to be a proarrhythmia due to the use‐dependent effect of the Na channel blockade with cibenzoline. In patients with arrhythmogenic substrates such as HCM, it is critical to pay attention to the proarrhythmic effects of class I antiarrhythmic drugs while increasing heart rate.     

布地奈德联合孟鲁司特钠治疗儿童哮喘的临床研究

目的：布地奈德气雾剂联合孟鲁司特钠咀嚼片在支气管哮喘患儿中的应用效果评价。方法将2013年5月~2014年5月深圳市龙岗区第三人民医院儿科门诊接治的70例轻-中度慢性持续期支气管哮喘患儿按照随机数字表法均分2组,在相同常规治疗及护理基础上：研究组35例患儿给予布地奈德气雾剂及口服孟鲁司特钠咀嚼片联合治疗,对照组35例患儿给予布地奈德气雾剂治疗,对两组患儿治疗1个疗程后的哮喘症状评分及随访期间哮喘控制情况进行综合比较。结果治疗1个疗程后,两组患儿日、夜间哮喘症状评分均有明显下降(P<0.05);研究组较对照组下降幅度更为显著(P<0.05);随访期间,研究组哮喘急性发作次数明显少于对照组(P<0.05);研究组无症状天数比例(87.50%)明显高于对照组(71.43%)(P<0.05);两组患儿均无严重药物不良反应情况发生。结论在常规治疗基础上给予慢性持续期支气管哮喘患儿布地奈德气雾剂联合孟鲁司特钠咀嚼片治疗可明显减轻患儿哮喘症状,有利于哮喘症状的长期控制,值得临床推广应用。